Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Pretreatment blood pressure reliably predicts progression of chronic nephropathies. GISEN Group.

Ruggenenti P, Perna A, Lesti M, Pisoni R, Mosconi L, Arnoldi F, Ciocca I, Gaspari F, Remuzzi G.

Kidney Int. 2000 Nov;58(5):2093-101.

4.
5.

Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.

Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G.

Lancet. 1999 Jul 31;354(9176):359-64.

PMID:
10437863
6.

Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.

Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G.

Am J Kidney Dis. 2000 Jun;35(6):1155-65.

PMID:
10845831
7.

ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy.

Ruggenenti P, Perna A, Remuzzi G; Gruppo Italiano di Studi Epidemiologici in Nefrologia.

J Am Soc Nephrol. 2001 Dec;12(12):2832-7.

11.

Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies. The "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).

Ruggenenti P, Perna A, Mosconi L, Matalone M, Pisoni R, Gaspari F, Remuzzi G.

Kidney Int Suppl. 1997 Dec;63:S54-7.

PMID:
9407422
12.

Retarding progression of chronic renal disease: the neglected issue of residual proteinuria.

Ruggenenti P, Perna A, Remuzzi G; GISEN Group Investigators.

Kidney Int. 2003 Jun;63(6):2254-61.

13.

The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.

Lea J, Greene T, Hebert L, Lipkowitz M, Massry S, Middleton J, Rostand SG, Miller E, Smith W, Bakris GL.

Arch Intern Med. 2005 Apr 25;165(8):947-53.

PMID:
15851648
14.

Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases.

Seeman T, Dusek J, Vondrák K, Flögelová H, Geier P, Janda J.

Am J Hypertens. 2004 May;17(5 Pt 1):415-20.

PMID:
15110900
15.

[Renoprotective effect of ramipril in children with chronic renal failure--the experience of one centre].

Peco-Antić A, Virijević V, Paripović D, Babić D.

Srp Arh Celok Lek. 2004 Oct;132 Suppl 1:34-8. Serbian.

PMID:
15615462
16.

Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.

Ruggenenti P, Perna A, Loriga G, Ganeva M, Ene-Iordache B, Turturro M, Lesti M, Perticucci E, Chakarski IN, Leonardis D, Garini G, Sessa A, Basile C, Alpa M, Scanziani R, Sorba G, Zoccali C, Remuzzi G; REIN-2 Study Group.

Lancet. 2005 Mar 12-18;365(9463):939-46.

PMID:
15766995
17.

Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies.

Cinotti GA, Zucchelli PC; Collaborative Study Group.

Nephrol Dial Transplant. 2001 May;16(5):961-6.

PMID:
11328901
18.

Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies.

Ruggenenti P, Pagano E, Tammuzzo L, Benini R, Garattini L, Remuzzi G.

Kidney Int. 2001 Jan;59(1):286-94.

19.

Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline?

van Essen GG, Apperloo AJ, Rensma PL, Stegeman CA, Sluiter WJ, de Zeeuw D, de Jong PE.

Kidney Int Suppl. 1997 Dec;63:S58-62.

PMID:
9407423
20.

Effect of ramipril on blood pressure and protein excretion rate in normotensive nondiabetic patients with proteinuria.

Toto RD, Adams-Huet B, Fenves AZ, Mitchell HC, Mulcahy W, Smith RD.

Am J Kidney Dis. 1996 Dec;28(6):832-40.

PMID:
8957034

Supplemental Content

Support Center